Lariat Suture Delivery Device 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 SentreHEART 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2015-07-14
  • 사례 출판 날짜
    2015-07-14
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: sentreheart lariat suture delivery device the united states food and drug administration (fda) has issued medical device safety alerts concerning lariat suture delivery device, manufactured by sentreheart. the fda is alerting health care providers and patients of reports of patient deaths and other serious adverse events associated with the use of the lariat suture delivery device and its associated devices to close the left atrial appendage, a pouch-like region of the left atrium in the heart, in patients with irregular heart rhythm (atrial fibrillation) to prevent stroke. the fda identified 45 adverse events through june 30, 2015 that occurred in patients undergoing left atrial appendage (laa) closure procedures with the lariat suture delivery device and/or its associated devices. these reports describe six patient deaths and other serious medical complications including laceration and/or perforation of the heart, complete laa detachment from the heart, bleeding (hemorrhage), low blood pressure (hypotension), fluid collection around the heart (pericardial effusion), fluid collection around the heart that causes low blood pressure and decreased heart function leading to shock (cardiac tamponade), and fluid collection around the lung (pleural effusion). of the 45 adverse events reported to the fda, 34 (approximately 75%) resulted in the need to perform emergency heart surgery. to reduce the risk of stroke in patients with atrial fibrillation, the fda advises healthcare professionals to consider treatment options for which safety and effectiveness have been established. prior to treatment, health professionals should inform atrial fibrillation patients of the benefits and risks of the available treatment options to help prevent stroke. for details, please refer to the fda websites: http://www.Fda.Gov/medicaldevices/safety/alertsandnotices/ucm454501.Htm http://www.Fda.Gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm454660.Htm if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 14 july 2015.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: SentreHEART Lariat Suture Delivery Device
  • Manufacturer

Manufacturer